JP2022514858A5 - - Google Patents

Info

Publication number
JP2022514858A5
JP2022514858A5 JP2021535273A JP2021535273A JP2022514858A5 JP 2022514858 A5 JP2022514858 A5 JP 2022514858A5 JP 2021535273 A JP2021535273 A JP 2021535273A JP 2021535273 A JP2021535273 A JP 2021535273A JP 2022514858 A5 JP2022514858 A5 JP 2022514858A5
Authority
JP
Japan
Prior art keywords
aqueous solution
composition according
solution composition
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535273A
Other languages
English (en)
Japanese (ja)
Other versions
JP7421556B2 (ja
JP2022514858A (ja
Filing date
Publication date
Priority claimed from GBGB1821149.0A external-priority patent/GB201821149D0/en
Priority claimed from GBGB1911581.5A external-priority patent/GB201911581D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/053655 external-priority patent/WO2020128507A1/en
Publication of JP2022514858A publication Critical patent/JP2022514858A/ja
Publication of JP2022514858A5 publication Critical patent/JP2022514858A5/ja
Application granted granted Critical
Publication of JP7421556B2 publication Critical patent/JP7421556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535273A 2018-12-21 2019-12-20 新規組成物 Active JP7421556B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1821149.0A GB201821149D0 (en) 2018-12-21 2018-12-21 Novel composition
GB1821149.0 2018-12-21
GB1911581.5 2019-08-13
GBGB1911581.5A GB201911581D0 (en) 2019-08-13 2019-08-13 Novel composition
PCT/GB2019/053655 WO2020128507A1 (en) 2018-12-21 2019-12-20 Novel composition

Publications (3)

Publication Number Publication Date
JP2022514858A JP2022514858A (ja) 2022-02-16
JP2022514858A5 true JP2022514858A5 (https=) 2022-12-21
JP7421556B2 JP7421556B2 (ja) 2024-01-24

Family

ID=69104798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535273A Active JP7421556B2 (ja) 2018-12-21 2019-12-20 新規組成物
JP2021535272A Pending JP2022514597A (ja) 2018-12-21 2019-12-20 新規組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021535272A Pending JP2022514597A (ja) 2018-12-21 2019-12-20 新規組成物

Country Status (9)

Country Link
US (2) US12239685B2 (https=)
EP (2) EP3897573A1 (https=)
JP (2) JP7421556B2 (https=)
KR (1) KR20210114000A (https=)
CN (2) CN113301885A (https=)
AU (1) AU2019411551A1 (https=)
BR (1) BR112021011753A2 (https=)
CA (1) CA3124529A1 (https=)
WO (2) WO2020128507A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) * 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN116726145A (zh) * 2022-03-04 2023-09-12 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CN100421726C (zh) 2006-03-06 2008-10-01 南京凯瑞尔纳米生物技术有限公司 包含有肽类药物的纳米复合物滴眼液及其制备方法
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2011062676A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20170348382A1 (en) * 2014-12-16 2017-12-07 Dr. Reddy's Laboratories Limited Lyophilized injectable compositions of daptomycin
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) * 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations

Similar Documents

Publication Publication Date Title
JP2022514858A5 (https=)
JP2014518276A5 (https=)
JP2015525762A5 (https=)
US5719119A (en) Parenteral nutrition therapy with amino acids
RU2013117209A (ru) Буферные глазные композиции и способы их применения
CA2672902A1 (en) Formulations
JP2022514597A5 (https=)
JP2010521994A5 (https=)
JP2004532217A5 (https=)
RU2012144771A (ru) Стабильные водные композиции белка mia/cd-rap
RU2006122638A (ru) Фармацевтический препарат, включающий антитело против рецептора egf
JP2011507530A5 (https=)
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
JP2013519720A5 (https=)
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
EP0250559A1 (en) Parenteral nutrition therapy with amino acids
JP2015110646A5 (https=)
JP2019533679A5 (https=)
GB2429205A (en) Salts of dihydrojasmonic acid and use thereof in agriculture
RU2004119056A (ru) Составленные на основе воды фармацевтические композиции водорастворимых пролекарств пропофола
WO2006103274A8 (fr) Inhibiteurs d'age
RU2019137020A (ru) Составы со сниженным окислением
Pope The neutralization of isoniazid activity in Mycobacterium tuberculosis by certain metabolites
BE1022290B1 (fr) Procede de fermentation
RU2014115289A (ru) Композиция пазопаниба